Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has received a consensus rating of “Moderate Buy” from the ten analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $19.1111.

FULC has been the topic of several recent analyst reports. The Goldman Sachs Group reissued a “positive” rating on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Truist Financial boosted their price target on shares of Fulcrum Therapeutics from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. HC Wainwright upped their price objective on shares of Fulcrum Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Wall Street Zen downgraded shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Finally, JPMorgan Chase & Co. began coverage on shares of Fulcrum Therapeutics in a research note on Monday, January 12th. They set an “overweight” rating and a $20.00 target price for the company.

Fulcrum Therapeutics Price Performance

FULC opened at $10.86 on Friday. The firm has a fifty day moving average price of $11.12 and a 200 day moving average price of $9.24. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $15.74. The stock has a market cap of $587.74 million, a P/E ratio of -9.20 and a beta of 3.19.

Insider Activity at Fulcrum Therapeutics

In other news, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the sale, the director owned 469,864 shares of the company’s stock, valued at $5,577,285.68. This represents a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the sale, the insider owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 4,205,139 shares of company stock valued at $58,711,943 over the last quarter. 7.00% of the stock is owned by company insiders.

Institutional Trading of Fulcrum Therapeutics

Large investors have recently bought and sold shares of the business. Acadian Asset Management LLC raised its holdings in shares of Fulcrum Therapeutics by 63.5% during the 2nd quarter. Acadian Asset Management LLC now owns 563,380 shares of the company’s stock worth $3,871,000 after acquiring an additional 218,819 shares during the period. Bailard Inc. purchased a new stake in shares of Fulcrum Therapeutics in the second quarter valued at about $185,000. Campbell & CO Investment Adviser LLC acquired a new stake in Fulcrum Therapeutics during the third quarter worth about $943,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in Fulcrum Therapeutics by 57.3% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,547 shares of the company’s stock worth $2,357,000 after purchasing an additional 124,798 shares during the period. Finally, Aberdeen Group plc purchased a new stake in shares of Fulcrum Therapeutics during the 2nd quarter valued at approximately $404,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.